Cargando…

Characterization of LDD-2633 as a Novel RET Kinase Inhibitor with Anti-Tumor Effects in Thyroid Cancer

Rearranged during transfection (RET), a receptor tyrosine kinase, is activated by glial cell line-derived neurotrophic factor family ligands. Chromosomal rearrangement or point mutations in RET are observed in patients with papillary thyroid and medullary thyroid carcinomas. Oncogenic alteration of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Hyo Jeong, Jeong, Pyeonghwa, Moon, Yeongyu, Choi, Jungil, Heo, Jeong Doo, Kim, Yong-Chul, Han, Sun-Young
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7825493/ https://www.ncbi.nlm.nih.gov/pubmed/33419162 http://dx.doi.org/10.3390/ph14010038

Ejemplares similares

Discovery of a FLT3 inhibitor LDD1937 as an anti-leukemic agent for acute myeloid leukemia
por: Lee, Hyo Jeong, et al.
Publicado: (2017)

Correction: Discovery of a FLT3 inhibitor LDD1937 as an anti-leukemic agent for acute myeloid leukemia
por: Lee, Hyo Jeong, et al.
Publicado: (2018)

Characterization of KRC-108 as a TrkA Kinase Inhibitor with Anti-Tumor Effects
por: Lee, Hyo Jeong, et al.
Publicado: (2022)

Chemical characterization and biological activity data for a novel indirubin derivative, LDD-1819
por: Kim, Woong-Hee, et al.
Publicado: (2019)

Characterization of the Indirubin Derivative LDD970 as a Small Molecule Aurora Kinase A Inhibitor in Human Colorectal Cancer Cells
por: Ndolo, Karyn Muzinga, et al.
Publicado: (2017)

RET kinase inhibitors for RET-altered thyroid cancers
por: Vodopivec, Danica M., et al.
Publicado: (2022)

PB2633: HEMOSTASIOLOGICAL CHANGES IN RHEUMATOID ARTHRITIS
por: Musayeva, Nargiza, et al.
Publicado: (2023)

Novel algorithms for LDD motif search
por: Xiao, Peng, et al.
Publicado: (2019)

Melatonin protects against cadmium-induced oxidative stress via mitochondrial STAT3 signaling in human prostate stromal cells
por: Hyun, Moonjung, et al.
Publicado: (2023)

The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers
por: Rosen, Ezra Y., et al.
Publicado: (2022)

Effect of Ocimum sanctum L as LDD in periodontal therapy
por: Deepika, Burra Anand, et al.
Publicado: (2023)

2633. Influenza and Tdap Vaccination Coverage among Pregnant Women in the PREVAIL Cohort
por: Schlaudecker, Elizabeth P, et al.
Publicado: (2019)

Author Correction: The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers
por: Rosen, Ezra Y., et al.
Publicado: (2022)

Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase
por: Moccia, Marialuisa, et al.
Publicado: (2015)

Oral Presentations (LDD, LPES, LNM, LPAT, LNT, LPPT, LPM)
Publicado: (2010)

SUN-LB75 The Anti-Tumor Activity of the Selective Ret Inhibitor Selpercatinib (LOXO-292) in Medullary Thyroid Cancer Is Independent of the Specific RET Mutation
por: Cabanillas, Maria E, et al.
Publicado: (2020)

Effects of Bisphenol A and Its Alternatives, Bisphenol F and Tetramethyl Bisphenol F on Osteoclast Differentiation
por: Kim, Hye-Min, et al.
Publicado: (2021)

Selective RET kinase inhibition for patients with RET-altered cancers
por: Subbiah, V, et al.
Publicado: (2018)

Design, Synthesis and Inhibitory Activity of Photoswitchable RET Kinase Inhibitors
por: Ferreira, Rubén, et al.
Publicado: (2015)

Anilinoquinazoline inhibitors of the RET kinase domain—Elaboration of the 7-position
por: Jordan, Allan M., et al.
Publicado: (2016)

Modulatory role of phospholipase D in the activation of signal transducer and activator of transcription (STAT)-3 by thyroid oncogenic kinase RET/PTC
por: Kim, Young-Rae, et al.
Publicado: (2008)

Precision therapy for RET-altered cancers with RET inhibitors
por: Thein, Kyaw Z., et al.
Publicado: (2021)

RET signaling pathway and RET inhibitors in human cancer
por: Regua, Angelina T., et al.
Publicado: (2022)

RET Fusion Genes in Korean Non-Small Cell Lung Cancer
por: Yoo, Seung Soo, et al.
Publicado: (2013)

EGF Induced RET Inhibitor Resistance in CCDC6-RET Lung Cancer Cells
por: Chang, Hyun, et al.
Publicado: (2017)

Involvement of RET oncogene in human tumours: specificity of RET activation to thyroid tumours.
por: Santoro, M., et al.
Publicado: (1993)

Response to RET-Specific Therapy in RET Fusion-Positive Anaplastic Thyroid Carcinoma
por: Dias-Santagata, Dora, et al.
Publicado: (2020)

Additive effect of oral LDD175 to tamsulosin and finasteride in a benign prostate hyperplasia rat model
por: Choi, Bo Ram, et al.
Publicado: (2018)

Durable Disease Control by RET Inhibitor Selpercatinib in a Heavily Pre-Treated RET Fusion-Positive Papillary Thyroid Cancer
por: Yokota, Tomoya
Publicado: (2022)

Another Case of De Novo 3q26.33q27.3 Microdeletion and Its Medicolegal Sequel
por: Indraccolo, Ugo, et al.
Publicado: (2018)

A mutation linked to degt-1(ok3307) in C. elegans strain VC2633 affects rpm-1
por: Jin, Eugene Jennifer, et al.
Publicado: (2022)

How to Treat a Signal? Current Basis for RET-Genotype-Oriented Choice of Kinase Inhibitors for the Treatment of Medullary Thyroid Cancer
por: Prazeres, Hugo, et al.
Publicado: (2011)

Targeted activity of the small molecule kinase inhibitor Pz-1 towards RET and TRK kinases
por: Moccia, Marialuisa, et al.
Publicado: (2021)

Precision oncology with selective RET inhibitor selpercatinib in RET-rearranged cancers
por: Gouda, Mohamed A., et al.
Publicado: (2023)

2633. Nasal Colonization Status of Respiratory Viruses in Patients During the COVID-19 Epidemic Period at a Tertiary Hospital in Japan
por: Katsuta, Tomohiro, et al.
Publicado: (2023)

A Case of Medullary Thyroid Carcinoma with de novo V804M RET Germline Mutation
por: Choi, Young Sik, et al.
Publicado: (2013)

On the RET Rearrangements in Chernobyl-Related Thyroid Cancer
por: Jargin, Sergei V.
Publicado: (2012)

Destabilizing RET in targeted treatment of thyroid cancers
por: Gild, M L, et al.
Publicado: (2015)

Corrigendum to “How to Treat a Signal? Current Basis for RET-Genotype-Oriented Choice of Kinase Inhibitors for the Treatment of Medullary Thyroid Cancer”
por: Prazeres, Hugo, et al.
Publicado: (2016)

Treatment of RET-Positive Advanced Medullary Thyroid Cancer with Multi-Tyrosine Kinase Inhibitors—A Retrospective Multi-Center Registry Analysis
por: Koehler, Viktoria Florentine, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_enprfnn012lkdhpsqfc412vhbq